Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic‐pharmacodynamic modelling
The PKPD model for PTH was completed with the unique data of a single patient who received PTH according to various dosing regimens, including continuous infusion. Continuous administration of PTH is favoured because it permanently increases the phosphate clearance and therefore needs to be further investigated.
Authors
- Daan J. Touw (ORCID: https://orcid.org/0000-0002-1429-4789)
- M. De Visscher (ORCID: https://orcid.org/0000-0002-6766-1570)
- Annika M.A. Berends (ORCID: https://orcid.org/0000-0002-8440-332X)
- Nieko Punt (ORCID: https://orcid.org/0000-0002-7655-6094)
- Anneke C. Muller Kobold (ORCID: https://orcid.org/0000-0003-3457-4179)
- Manon Schuls‐Fouchier
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1111/bcp.16342
- Citations
- 1
- Primary Topic
- Thyroid and Parathyroid Surgery
- Type
- article
- Field-Weighted Citation Impact
- 0.57